Raymond James initiates QXO stock with Outperform rating on acquisition strategy
WATERTOWN, Mass. - Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a biopharmaceutical company with a market capitalization of $193 million and strong liquidity position, announced Wednesday the death of Paul J. Mellett Jr., the company’s Chief Financial and Administrative Officer who served the biopharmaceutical firm for more than two decades. According to InvestingPro data, the company maintains a healthy current ratio of 5.0, indicating robust short-term financial stability.
Mellett joined Enanta in September 2003, establishing the company’s finance department and playing a key role in its 2013 initial public offering. He was instrumental in forming strategic partnerships, including the 2006 collaboration with Abbott (now AbbVie) that led to the development of hepatitis C treatments VIEKIRA PAK and MAVYRET/MAVIRET, which have treated over one million patients globally. Despite recent market challenges, the stock has shown resilience with a 56.5% year-to-date return, though analyst targets suggest further upside potential.
"Paul’s leadership and generosity of spirit have been at the core of Enanta," said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals, in a press release statement.
Prior to Enanta, Mellett served as Senior Vice President and Chief Financial Officer at Essential Therapeutics and as Chief Financial Officer at GelTex Pharmaceuticals, which was acquired by Genzyme Corporation in December 2000. His career also included positions as Chief Financial Officer at Marshall Contractors and as Audit Partner at Deloitte & Touche LLP.
A Boston College graduate, Mellett served on the board of Xaverian Brothers High School for 12 years and was a board member for Norwood Hospital and Big Brothers Big Sisters of Boston.
As previously announced, Harry R. Trout, III and Kathleen S. Capps, CPA, have been appointed as the company’s interim principal financial officer and principal accounting officer, respectively.
Enanta Pharmaceuticals focuses on developing small molecule drugs for virology and immunology, with current clinical programs targeting respiratory syncytial virus (RSV). While currently operating at a loss with negative EBITDA, InvestingPro analysis indicates the stock is trading below its Fair Value, with analyst price targets ranging up to $25. For deeper insights into Enanta’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Enanta Pharmaceuticals reported fiscal third-quarter 2025 results that exceeded both analyst and consensus expectations, driven by strong revenues and continued expense reductions. The U.S. Food and Drug Administration has approved an expanded indication for MAVYRET as the only eight-week treatment for acute hepatitis C virus infection, demonstrating a 96% cure rate in clinical trials. Enanta Pharmaceuticals has also filed a patent infringement lawsuit against Pfizer in the Unified Patent Court of the European Union over the COVID-19 antiviral Paxlovid, seeking a determination of liability for alleged infringement of its European patent.
Citizens JMP analyst Roy Buchanan raised the price target for Enanta Pharmaceuticals to $25 from $24, maintaining a Market Outperform rating. H.C. Wainwright assumed coverage on Enanta Pharmaceuticals with a Buy rating and a $20.00 price target, citing a favorable risk-reward profile at current share levels. Analysts from Citizens JMP previously raised the stock price target to $24 from $23, focusing on the company’s ongoing efforts in immunology. Enanta Pharmaceuticals plans to report Phase 2 results for its oral RSV therapeutic candidate, zelicapavir, in the third quarter, though further development will require a partnership. The company has noted the availability of antivirals for HBV and SARS-CoV-2 for partnering, but there are concerns that the RSV candidate may not progress without a partner.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.